AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 212 min read$IART

Integra Life falls as tissue reconstruction woes add to flooding worries in Q3

Integra LifeSciences (IART) shares fell to a May low after Q3 2026 results missed revenue estimates. Revenue was $411.2M, up 2% YoY but below consensus by $0.9M, impacted by a $7M headwind and weaker Tissue Reconstruction performance. Gross margin declined 500 bps to 51%, while adjusted net income rose 12% YoY to $46.4M, beating estimates by $0.03 per share. Q4 and full-year outlooks were set below consensus.

Original reporting
tradingview.com
Published Oct 21, 2026, 5:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 5:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Integra Life falls as tissue reconstruction woes add to flooding worries in Q3 — source image
Source · tradingview.com
Decision brief

The 30-second read

$IARTBearishHigh
01

Why it matters

The earnings miss and flood‑related cost introduce near‑term downside risk, but the adjusted EPS beat and growth in Specialty Surgery provide a partial cushion.

02

Market read

The earnings release is the primary catalyst for IART's price movement today, with potential spill‑over to the broader MedTech sector.

03

What to watch

The Specialty Surgery segment posted a 4% YoY revenue increase, which could offset concerns if the tissue‑reconstruction unit recovers.

Relevance 7/10Novelty 8/10Timing: after‑hours reaction

Background

Integra LifeSciences (IART) is a MedTech company focused on neurosurgery and tissue reconstruction. The Q3 release includes both financial results and an operational disruption note.

Company-level read

Ticker impact

$IARTBearishMedium confidence
Context

Integra LifeSciences reported Q3 2026 results that missed revenue estimates and highlighted a $7M flood‑related impact on its Cincinnati facility.

Expected impact

likely pressure as investors price in the revenue shortfall and operational setback

Evidence & confidence

Revenue fell short of consensus and guidance was lowered; the flood hit adds a tangible cost drag, prompting short‑term sell‑off.

Market effects

Sector

MedTech and tissue‑reconstruction segments may see heightened scrutiny on supply‑chain resilience.

Regional

Cincinnati‑area industrial activity could face short‑term concerns, but limited broader regional effect.

Global

Limited to investors tracking US‑listed MedTech earnings; no global macro impact.

Counterpoint

What could challenge this read

If the flood impact is one‑off, the stock may be oversold and could rebound on the back of a solid adjusted EPS beat.

Key entities

  • Company
    Integra LifeSciences

    US‑listed MedTech firm (ticker IART) reporting Q3 2026 results.

Read at source← All news

Also covered by

6 outlets

Related articles

OCT 21
$IARTMed

Integra LifeSciences (IART) Reports Q3 Revenue In Line with Guid

Integra LifeSciences (IART) reported Q3 revenue of $411M, meeting the lower end of its guidance. The company lowered its full-year revenue outlook by $30M due to operational disruptions. IART's P/S ratio is 0.57, below historical and industry averages. The company has a GF Score of 69, indicating mixed fundamentals with strengths in momentum and profitability but weaknesses in growth and financial strength. Insider activity shows net buying of $0.1M, while institutional interest is mixed.

gurufocus.com3 min
OCT 21
$IARTHighAI 8/10

Integra (IART) Q3 2026 Earnings Call Transcript

Integra (IART) reported Q3 2026 adjusted EPS of $0.59, with revenue at $411.2M, impacted by Cincinnati flooding. Operating cash flow was $96M. Full-year revenue guidance was reduced by $30M due to flooding and mixed portfolio performance. Tissue Reconstruction revenue is expected to be flat. The company reduced leverage to 3.8x and completed debt refinancing, strengthening its balance sheet.

finance.yahoo.com3 min
OCT 21
Med

Integra LifeSciences Holdings Corporation Q3 2026 Earnings Call Summary

Integra LifeSciences reported Q3 2026 earnings, citing a $7M revenue hit from Cincinnati flooding. Neurosurgery grew 6.5% organically, offsetting weaker segments. Tissue Reconstruction showed mixed results. The company refinanced $2.1B in debt. Management expects 2027 revenue to be impacted by $15M-$20M in Q1 and Q2 due to ongoing disruption. Earnings growth is projected to be supported by cost savings and a SurgiMend relaunch.

finance.yahoo.com2 min
OCT 21
$IARTMed

Why Integra LifeSciences (IART) stock is falling today

Integra LifeSciences (IART) shares fell 7.3% after reporting Q3 revenue of $411.2M, meeting expectations, and adjusted EPS of $0.59, beating estimates. The company cited plant flooding and operational disruptions, projecting Q4 revenue of $413M-$433M, below analyst estimates of $433.2M. Rising borrowing costs also weighed on investor sentiment.

financialcontent.com2 min
OCT 21
$IARTHighAI 8/10

What Integra LifeSciences (IART) Said on Its Q3 Earnings Call

Integra LifeSciences (IART) reported Q3 revenue of $304.1M, with neurosurgery growing 6.5% organically. Tissue Reconstruction revenue declined 2.2% to $107.1M. The company reaffirmed its full-year revenue outlook of $1.634B-$1.654B but reduced the midpoint by $30M. It expects 2027 revenue and EPS growth, supported by SurgiMend relaunch and PriMatrix momentum. Net debt was $1.5B at quarter-end, with leverage at 3.8x.

finance.yahoo.com2 min